Phase 2b oral COVID-19 pill vaccine sentinel cohort reported no vaccine-related serious adverse events; topline efficacy and safety data for approximately 5,400 participants are due in H1 2027.
Quarterly results
Vaxart posted a Q2 net loss of USD 13.5 million, narrowing from a USD 15 million loss a year earlier; loss per share improved to USD 0.06.
Revenue fell 31.53% to USD 27.2 million, mainly from government contracts, including USD 2.9 million tied to the Dynavax collaboration.
R&D expenses dropped 32.16% to USD 33.7 million, due to lower COVID-19 trial, personnel, facilities, preclinical, and manufacturing costs.
Liquidity and runway
Cash, cash equivalents, and investments totaled USD 64 million at June 30, with runway projected into Q2 2027.
VXRT•
